AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease

The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

Study Overview

• Status: Terminated
• Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease
• Intervention / Treatment: Drug: Pioglitazone; Drug: Placebo

Detailed Description

The drug being tested in this study is called pioglitazone. This study is designed to further evaluate the safety and effectiveness of pioglitazone on cognitive function in participants who have completed the AD-4833/TOMM40_301. This study will look at the effectiveness of pioglitazone on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study with a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

The study enrolled 40 participants, but is dependent on how many decide to continue treatment in an extension phase after completing the main (301) study. Participants will continue to receive the same study medication they received during the pivotal AD-4833/TOMM40_301 study, either:

• Pioglitazone 0.8 mg tablets or
• Placebo (this is a tablet that looks like the study drug but has no active ingredient).

All participants will be asked to take one tablet at the same time each day throughout the study.

This multi-centre trial, like its precedent pivotal trial, will be conducted worldwide. The overall time to participate in this study is minimum 2 years and a maximum of 7 years depending on when participants roll over from the 301 study. Participants will make approximately 2 visits per year to the clinic, and will be contacted by telephone 3 months after each treatment visit for a follow-up assessment, and 2 weeks after the final visit.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • North Ryde, New South Wales, Australia, 2113
  • Queensland
    • Southport, Queensland, Australia, 4215
  • Victoria
    • Heidelberg West, Victoria, Australia, 3081
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
• Switzerland
  • Basel, Switzerland, CH-4012
• United Kingdom
  • Avon
    • Bristol, Avon, United Kingdom, BS16 1LE
  • Devon
    • Exeter, Devon, United Kingdom, EX2 5DW
    • Plymouth, Devon, United Kingdom, PL6 8DH
  • Greater London
    • Hammersmith, Greater London, United Kingdom, W6 8RF
    • London, Greater London, United Kingdom, EC1M 6BQ
  • Greater Manchester
    • Manchester, Greater Manchester, United Kingdom, M13 9NQ
  • Lancashire
    • Blackpool, Lancashire, United Kingdom, FY2 0JH
  • Middlesex
    • Isleworth, Middlesex, United Kingdom, TW7 6FY
  • Strathclyde
    • Glasgow, Strathclyde, United Kingdom, G20 0XA
  • Tayside Region
    • Perth, Tayside Region, United Kingdom, PH2 7BH
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
    • Sun City, Arizona, United States, 85351
  • California
    • San Diego, California, United States, 92103
  • Florida
    • Delray Beach, Florida, United States, 33445
    • Fort Myers, Florida, United States, 33912
    • Lake Worth, Florida, United States, 33449
    • Melbourne, Florida, United States, 32940
    • Merritt Island, Florida, United States, 32952
    • Port Orange, Florida, United States, 32127
    • Saint Petersburg, Florida, United States, 33709
    • Weston, Florida, United States, 33331
  • Georgia
    • Atlanta, Georgia, United States, 30329
    • Decatur, Georgia, United States, 30033
  • Illinois
    • Chicago, Illinois, United States, 60640
    • Elk Grove, Illinois, United States, 60007
    • Elk Grove Village, Illinois, United States, 60007
  • Iowa
    • Iowa City, Iowa, United States, 52242
  • Missouri
    • Saint Louis, Missouri, United States, 63141
  • Nevada
    • Las Vegas, Nevada, United States, 89106
  • New Jersey
    • Marlton, New Jersey, United States, 08053
  • New York
    • New York, New York, United States, 10019
  • North Carolina
    • Concord, North Carolina, United States, 28025
    • Durham, North Carolina, United States, 27705
  • Ohio
    • Akron, Ohio, United States, 44320
  • South Carolina
    • Charleston, South Carolina, United States, 29401
  • Texas
    • Houston, Texas, United States, 77030
  • Utah
    • Salt Lake City, Utah, United States, 84107
  • Wisconsin
    • Middleton, Wisconsin, United States, 53562

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) without ongoing serious adverse events (SAEs) from AD-4833/TOMM40_301.
2. Is male or female and is at least 65 years of age at the time of the Baseline Visit.
3. In the opinion of the investigator, is capable of understanding and complying with the protocol requirements.
4. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
5. Must be living independently or in nonmedical residential care.
6. Has a project partner able to separately consent on his/her own behalf and take part in the study (with the intent to do so as long as the participant is enrolled), providing information on the cognitive, functional, and behavioral status of the participant and assisting with observation of adverse events (AEs) and monitoring of study medication, if needed. Project partners participating in the pivotal AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this capacity.

Exclusion Criteria:

1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of AD dementia.
2. Has a current diagnosis of significant psychiatric illness, per Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the participant has a current diagnosis or history of schizophrenia or bipolar disorder.
3. Has a glycosylated hemoglobin (HbA1c) >8% at the extension study Baseline Visit or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist.
4. Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass surgery), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
5. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, pivotal, child, sibling) or may consent under duress.
6. Is required to take excluded medications.
7. Has a history of hypersensitivity or allergies to pioglitazone or related compounds.

8. Had any of the following values at the extension study Baseline Visit:

   1. A serum total bilirubin value >15 x upper limit of normal (ULN).
   2. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 x ULN.
   3. Unexplained microscopic/macroscopic hematuria on 2 repeat examinations within 2 weeks.
9. Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the participant from adequately participating in the study or continue for the anticipated duration of the study.
10. Has received any investigational compound, with the exception of treatment during the AD-4833/TOMM40_301 study, within 30 days prior to Baseline or 5 half-lives prior to Baseline or is currently participating in another study that entails the administration of an investigational or marketed drug, supplement, or intervention including, but not limited to diet, exercise, lifestyle, or invasive procedure.
11. Has any cancer that has been in remission for less than 2 years from the extension study Baseline Visit. Participants with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Participants with current diagnosis of bladder cancer are not eligible irrespective of the remission status.
12. Has a current diagnosis of macular edema, degeneration or any maculopathy.
13. Has a history or current diagnosis of congestive heart failure (CHF), New York Heart Association class III-IV.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pioglitazone 0.8 mg; Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.	Drug: Pioglitazone; Pioglitazone tablets; Other Names: AD-4833
Placebo Comparator: Placebo; Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.	Drug: Placebo; Pioglitazone placebo-matching tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24	Composite scores were derived from the test battery. Each test in the battery falls into 1 of the following cognitive domains: Episodic Memory (California Verbal Learning Test - 2nd Edition [CVLT-II], Brief Visuospatial Memory Test - Revised [BVMT-R]), Executive Function (Trail Making Part B, Digit Span Backwards), Language (Animals, Lexical/Phonemic Fluency), Attention (Digit Span Forward, Trail Making Part A), and Visuospatial (Clock Drawing, BVMT-Copy). Only the domains of episodic memory, executive function, language, and attention were used for the calculation of composite score (i.e., Clock Drawing, BVMT-Copy, and the Multilingual Naming Test (MINT), which do not allow generation of standard z scores, were only used for diagnostic purposes and were excluded from the calculation of the composite score). To form the composite, z-scores were calculated for each test, each z-score for the domain were averaged, and then all relevant domains were averaged to form the composite.	Baseline and Month 24

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to Diagnosis of Alzheimer's Disease (AD) Dementia	Day 1 and every 6 months (up to maximum of 36 months)

Collaborators and Investigators

• Sponsor: Takeda

Study record dates

Study Major Dates

• Study Start (Actual): February 12, 2015
• Primary Completion (Actual): January 31, 2018
• Study Completion (Actual): May 8, 2018

Study Registration Dates

• First Submitted: November 4, 2014
• First Submitted That Met QC Criteria: November 4, 2014
• First Posted (Estimate): November 6, 2014

Study Record Updates

• Last Update Posted (Actual): July 2, 2019
• Last Update Submitted That Met QC Criteria: June 11, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: Drug therapy
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Cognition Disorders; Alzheimer Disease; Cognitive Dysfunction; Hypoglycemic Agents; Physiological Effects of Drugs; Pioglitazone
• Other Study ID Numbers: AD-4833/TOMM40_303; U1111-1154-9637 (Registry Identifier: WHO); 2013-004984-30 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes